Repositioning Candidate Details
Candidate ID: | R0880 |
Source ID: | DB05825 |
Source Type: | investigational |
Compound Type: | small molecule |
Compound Name: | NCX 1015 |
Synonyms: | -- |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA. |
CAS Number: | -- |
Molecular Weight: | |
DrugBank Indication: | Investigated for use/treatment in arthritis and arthritic pain and inflammatory bowel disease. |
DrugBank Pharmacology: | -- |
DrugBank MoA: | NCX-1015 is the prototype of a new class of glucocorticoids, the nitro-steroids, capable of enchancing anti-inflammatory properties and reduced side effects. It also abrogates the plasma levels of a catabolite of cartilage and bone metabolism, indication of a disease modifying action. |
Targets: | -- |
Inclusion Criteria: | Therapeutic strategy associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I11 | 5295 | Intestinal disease | A gastrointestinal system disease that is located_in the intestine. http://en.wikipedia.org/wiki/Human_gastrointestinal_tract | disease of anatomical entity/gastrointestinal system disease | Details |
I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |